Feb 10, 2026 04:05PM
Jan 12, 2026 04:05AM
Jan 11, 2026 04:00PM
Dec 12, 2025 10:31AM
Nov 4, 2025 04:27PM
Nov 4, 2025 04:05PM
Jul 28, 2025 04:05PM Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025 04:07PM
Feb 11, 2025 04:05PM
Jan 12, 2025 04:00PM
Oct 29, 2024 04:05PM
Aug 6, 2024 04:05PM
Apr 30, 2024 04:05PM
Feb 6, 2024 04:05PM Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
Jan 8, 2024 05:25AM
Jan 7, 2024 04:00PM
Sep 12, 2023 08:03AM
Sep 12, 2023 08:00AM
Aug 1, 2023 04:05PM
May 9, 2023 04:05PM
Apr 13, 2023 04:11PM Exelixis (EXEL) Advances Board Refreshment Plan
Apr 13, 2023 04:11PM
Mar 20, 2023 07:00AM
Mar 20, 2023 07:00AM
Feb 7, 2023 04:05PM
Jan 9, 2023 04:58AM
Jan 8, 2023 04:00PM
Jan 4, 2023 09:00AM Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer
Dec 1, 2022 06:23AM
Nov 3, 2022 08:05AM
Nov 3, 2022 08:00AM
Nov 1, 2022 04:08PM
Nov 1, 2022 04:07PM
Nov 1, 2022 04:07PM
Nov 1, 2022 04:06PM Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
Nov 1, 2022 04:05PM
Aug 9, 2022 04:05PM
Jul 7, 2022 12:00AM
Jun 16, 2022 12:00AM
May 10, 2022 04:05PM
Apr 13, 2022 04:06PM
Apr 13, 2022 04:05PM Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Feb 17, 2022 04:05PM
Jan 10, 2022 05:48AM
Jan 9, 2022 04:00PM
Jan 6, 2022 08:00AM
Nov 2, 2021 04:05PM
Oct 14, 2021 08:30AM
Oct 14, 2021 08:04AM Exelixis (EXEL), STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
Oct 14, 2021 08:00AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All